PURMX Therapeutics, Inc.

PURMX Therapeutics, Inc. is a Japanese biopharmaceutical venture company established in 2021 as a spin-off from Hiroshima University. The company specializes in the development of innovative nucleic acid medicines based on natural microRNA (miRNA) technology. Utilizing a proprietary functional RNA screening platform, PURMX identifies miRNAs capable of acting as gene regulators to control the expression of critical genes involved in disease. Their approach centers on the concept of an aging switch, aiming to induce cell senescence and death specifically in cancer cells. Unlike conventional small molecules or antibody therapies, their miRNA-based modality is designed to simultaneously suppress multiple pathways that drive tumor growth and can be applied to a broad range of gene-related conditions.

The company’s core focus is addressing high unmet medical needs in oncology, particularly for intractable diseases like malignant pleural mesothelioma and recurrent head and neck cancer. Their lead candidate, MIRX002 (containing miR-3140-3p), has progressed into clinical trials to evaluate its therapeutic efficacy and safety in humans. By leveraging an experienced leadership team with extensive backgrounds in pharmaceutical regulatory affairs, clinical development, and quality assurance, PURMX aims to transition academic research into viable clinical assets. The company actively collaborates with global partners and regulatory bodies, including receiving Orphan Drug Designation from the U.S. FDA, to advance its pipeline and potentially transform treatment standards for patients suffering from difficult-to-treat cancers.